Destiny Pharma and SporeGen® announce collaboration and Innovate UK grant award to co-develop novel, preventative treatment for COVID-19

Link to Full Article Destiny Pharma and SporeGen® announce collaboration and Innovate UK grant award to co-develop novel, preventative treatment for COVID-19 SPOR-COV™ prophylactic approach targets the innate immune system with potential to develop COVID-19 protection within a few days of treatment Innovate UK grant of £800,000 to support SPOR-COV™ programme over the next 18 months […]

Adherium Annual Report

Link to Full Report

CalciMedica Announces Peer-Reviewed Publication of Positive COVID-19 Data and Initiation of Blinded, Placebo-Controlled Trial of Auxora™ in Patients with Severe COVID-19 Pneumonia

Link to Full Article Study published in Critical Care journal shows patients with severe COVID-19 pneumonia treated with Auxora and standard of care had substantially improved outcomes compared to patients on standard of care alone Clinical trial to enroll up to 400 patients at sites across the U.S., including California, Texas and Louisiana, is being […]

Destiny Destiny Pharma welcomes NBIC #BiofilmAware campaign, launched today

Link to Full Article Destiny Pharma, as an NBIC industrial partner, is currently working on three NBIC funded research projects in collaboration with expert teams at the Universities of Cardiff, Sheffield and Southampton. The XF drug platform has demonstrated efficacy against bacteria in biofilms and we are looking forward to advancing these research assets towards […]

Armata Pharmaceuticals Announces Second Quarter 2020 Results and Provides General Corporate Update

Link to Full Article MARINA DEL REY, Calif., Aug. 13, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the second quarter of 2020 and provided a corporate and clinical update. During the […]

Destiny Pharma’s positive interim safety review of Phase 2b clinical trial of lead asset XF-73 in the prevention of post-surgical bacterial infections

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive interim safety review of Phase 2b clinical trial of lead asset XF-73 in the prevention of post-surgical bacterial infections Brighton, United Kingdom – 11 August 2020 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel […]

Adherium appoints Mr Geoff Feakes as Chief Technology Officer

Link to Full Article Melbourne, Australia – 5 August 2020: Adherium Limited (ASX: ADR) a leader in digital inhaled device adherence, remote monitoring and data management solutions, has appointed Mr Geoff Feakes as Chief Technology Officer (CTO) leading the Company’s R&D and Innovation teams supporting Adherium’s revised business strategy. Mike Motion, Adherium CEO noted: “I […]

Destiny Pharma’s Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections

Protocol amendment agreed with FDA to reduce Phase 2b study size without compromising its statistical power or clinical value Study two thirds enrolled. Recruitment now expected to complete by year end Planned study interim safety review to be announced in August 2020 Brighton, United Kingdom – 27 July 2020 – Destiny Pharma plc (AIM: DEST), […]

CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies

Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate its drug discovery pipeline La Jolla, Calif., USA; Szeged and Budapest, Hungary July 15, 2020 – CalciMedica, a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of […]

CalciMedica Announces Data Showing Auxora™ Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia

Link to Full Article Median time to recovery was more than two times faster for patients treated with Auxora plus standard of care compared to standard of care alone The percentage of patients requiring invasive mechanical ventilation was 2.8 times lower with Auxora plus standard of care compared to standard of care alone Treating 2.6 […]